(S)-1-tert-butyl-N-(3-methyl-7-(2-(1-methyl-1H-pyrazol-4-ylamino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)-1H-1,2,3-triazole-4-carboxamide

ID: ALA5073995

Chembl Id: CHEMBL5073995

PubChem CID: 135355890

Max Phase: Preclinical

Molecular Formula: C26H32N10O

Molecular Weight: 500.61

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1CCc2cc(-c3ccnc(Nc4cnn(C)c4)n3)ccc2[C@H](NC(=O)c2cn(C(C)(C)C)nn2)C1

Standard InChI:  InChI=1S/C26H32N10O/c1-26(2,3)36-16-23(32-33-36)24(37)30-22-15-34(4)11-9-17-12-18(6-7-20(17)22)21-8-10-27-25(31-21)29-19-13-28-35(5)14-19/h6-8,10,12-14,16,22H,9,11,15H2,1-5H3,(H,30,37)(H,27,29,31)/t22-/m1/s1

Standard InChI Key:  UQBXNYTXHLBRME-JOCHJYFZSA-N

Alternative Forms

  1. Parent:

    ALA5073995

    ---

Associated Targets(Human)

BTK Tclin Tyrosine-protein kinase BTK (8973 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CD69 Tchem Early activation antigen CD69 (107 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 500.61Molecular Weight (Monoisotopic): 500.2761AlogP: 2.93#Rotatable Bonds: 5
Polar Surface Area: 118.68Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 10.68CX Basic pKa: 7.80CX LogP: 3.03CX LogD: 2.49
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.43Np Likeness Score: -1.69

References

1. Hopkins BT, Bame E, Bajrami B, Black C, Bohnert T, Boiselle C, Burdette D, Burns JC, Delva L, Donaldson D, Grater R, Gu C, Hoemberger M, Johnson J, Kapadnis S, King K, Lulla M, Ma B, Marx I, Magee T, Meissner R, Metrick CM, Mingueneau M, Murugan P, Otipoby KL, Polack E, Poreci U, Prince R, Roach AM, Rowbottom C, Santoro JC, Schroeder P, Tang H, Tien E, Zhang F, Lyssikatos J..  (2022)  Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.,  65  (2.0): [PMID:34734694] [10.1021/acs.jmedchem.1c00926]

Source